Alejandro Olivares-Hernández, Jonnathan Roldán-Ruiz, José Pablo Miramontes-González, Irene Toribio-García, Juan Luis García-Hernández, Luis Posado-Domínguez, Lorena Bellido-Hernández, Juan Jesús Cruz-Hernández, Emilio Fonseca-Sánchez, Edel Del Barco-Morillo
BACKGROUND: Non-small cell lung cancer (NSCLC) has undergone a major change in the last decade in terms of survival and prognosis due to the introduction of new drugs in the last 10 years. One of the drugs with the most promising preliminary results in NSCLC are PARP inhibitors (iPARPs), whose clinical trials have very heterogeneous results. The use of iPARPs in NSCLC may lead to increased survival in several selected patients, and their use may become a standard in the coming years. However, there is currently controversy about the efficacy and safety of these drugs in NSCLC...
December 2023: Chinese Clinical Oncology